prioriti review week march
may miss past week
 realli valu time case miss anyth provid quick summari major event past eek
key event atch upcom eek also link research model applic highlight
frequent inbound question debat topic come investor minut read pleas let us
celgen acceleron announc submiss luspatercept bla fda submiss luspatercept low
intermedi risk myelodysplast syndrom md transfusion-depend beta-thalassemia ere base phase
medalist believ studi respect compani plan submit market applic ema
johnson johnson car-t grant prime design grant prime design
european medicin agenc asset b-cell matur antigen bcma design base result
phase studi evalu car-t cell phase studi evalu
gilead submit snda fda descovi hiv prep gilead use prioriti review voucher ith file result
expect review file base phase discov trial hich descovi show ed noninferior truvada
prevent infect high-risk particip show ed particip receiv descovi statist signific
improv renal bone laboratori paramet compar ith receiv truvada
merck keytruda approv china nsclc keytruda approv nation medic product administr nmpa
combin ith pemetrex platinum chemotherapi metastat nsclc ith egfr tumor aberr
approv grant base data seen phase studi
su novarti aimovig accus tri avoid compani agreementsw hich began
develop market migrain drug aimovig novarti alleg action ere attempt keep aimovig profit amgen
alon drug approv us last year
receiv market author eu vizimpro drug approv monotherapi treatment
adult patient ith local advanc metastat nsclc ith egfr-activ mutat approv base data archer-
alexion settl justic depart hile admit rongdo compani accus use
chariti help cover medicar patient out-of-pocket drug cost path push use alexion medic
govern alleg incid began pertain foundat cover use soliri
vertex appoint new cfo compani hire charl agner new cfo effect april mr agner join vertex
ortho clinic diagnost serv cfo evp financ
announc price global offer compani expect close offer occur april
rais come dbv report prior cash posit ould last submiss bla hich expect
ironwood complet separ cyclerion therapeut previous announc compani spun cyclerion becom
gi-focus healthcar compani led linzess franchis spin-off compani cyclerion ill focu solubl guanyl
achillion complet enrol phase trial studi six-month blind placebo-control trial
assess patient ith glomerulopathi ill assess safeti efficaci factor inhibitor
biohaven enrol first patient phase trial studi double-blind placebo-control dose-rang
trial intranas administ cgrp receptor antagonist acut treatment migrain
acceleron discontinu phase asset compani announc discontinu hich system muscl
agent develop potenti treatment neuromuscular disord discontinu result frequenc
anti-drug antibodi ada observ among subject format ada associ ith advers event
acceleron announc departur chief medic offic chang effect april search replac
alreadi begun
proprietari research past week
 replay transcript quot ceo/cfo call
 takeaw ay kra dinner
 aacr updat kra buzz all-tim high
 replay transcript quot ceo/cfo call
 biopharmaceut highlight plenari session
client ask
investor ask follow ing topic phone call email in-person market meet
think probabl compon cvr associ bristol/celgen deal
iss glass-lew recommend bristol sharehold vote favor deal investor focu begun
shift tow ard probabl cvr pay-out cvr pay-out requir approv ozanimod
 estim high probabl success approv although combin probabl
three approv less assum probabl ozanimod approv given posit data
level focu given resolv defici packag result rtf letter encourag recent
nda re-fil see prospect anoth rtf extrem unlik anticip approv late
give probabl approv slightli low er asset cvr celgen show
compel data delay file allow data matur hich could allow better label ever delay file also
take anticip approv date closer deadlin ell introduc higher risk unanticip safeti signal
could aris meantim think final cvr asset probabl approv given
encourag data present ell unmet need later-lin patient think approv like
learn kra investor interest kra high confer ith three amgen oral
session maximum capac hile long identifi varieti solid tumor indic abil identifi
common mutat ithin kra protein found mani cancer identifi compound bind specif mutat
emerg potenti treatment path taken develop multipl player name
mirati hile signific buzz around short half-lif think strong synergist action show
present combin ith agent like meki chemotherapi could prove differenti
factor expect phase data ill present first time june ith
emphasi hat orr data ill look like comparison mirati asset expect later year base feedback
 eve receiv investor think expect orr data quit high said see real valu asset
like root combin therapi
takeaway i/o space confer detail share sever keytruda trial
support view continu expans addit indic pool analysi previous present data
small cell lung cancer sclc orr cr ith median os
month durat respons month median dor reach hile data previous de-risk see
support approv sclc hich pdufa date upcom june addit merck present post hoc
analysi keytruda/chemo combo nsclc patient ith liver brain metastas ith combo show ing
os hr patient ith liver met patient ith brain met compar ith chemotherapi
watch week ahead
clinic trial read-out regulatori event expect near term
acmg american colleg medic genet annual clinic meet seattl april
ishlt societi heart lung transplant annual meet scientif session orlando fl april
easl european associ studi liver intern liver congress geneva sw itzerland april
futur leader biotech industri biocenturi new york ny april
intern societi nephrolog orld congress melbourn australia april
escmid european societi clinic microbiolog infecti diseas congress amsterdam netherland april
let us know question comment geoff scott greg olivia jason
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
